Navigation Links
Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona
Date:4/13/2012

SILVER SPRING, Md., April 13, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS has entered into an advertising and promotion agreement ("Agreement") with a major pro sports team based in the state of Arizona (the "Team") for the marketing of Clotamin.  The Agreement is part of new marketing initiatives to promote and launch Clotamin in 240 Walgreens throughout Arizona.

Under terms of the Agreement, HDS, in conjunction with Walgreens, will have the right to make use of the Team name and logo in connection with an in-store Clotamin promotion, including the prominent placement of counter point-of-sale (POS) displays in all Walgreens locations in the state of Arizona for the duration of the promotion – approximately five months, beginning on June 1, 2012. 

During the consumer promotion and advertising program, Clotamin will be featured at Team home games on signage and other marketing elements throughout the University of Phoenix Stadium in Glendale, Arizona.  Team fans will be encouraged to visit their local Walgreens location, pick-up an entry form at the Team vendor display, and register for the opportunity to experience a Team home game in the comfort of an exclusive private box.  One lucky winner each month (4 total) will receive a private box for a Team home game, including game tickets, VIP parking passes, and a food and beverage package for 16 guests.  Also included in the exclusive prize package experience is special personal appearance by the Team mascot/cheerleaders and 16 team gift bags. 

"Similar to our pro sports team deal to market Clotamin with Walgreens in Oregon, this new agreement in Arizona is designed to leverage our advertising capabilities to grow awareness and acceptance of Clotamin with strong endorsements and strategic sponsorships," stated Mackie A. Barch, CEO of Sunpeaks Ventures. "The marketing combination of pharmacy powerhouse Walgreens and a highly-recognizable pro sports team is designed to allow us to quickly introduce Clotamin to a statewide audience of loyal customers and fans.  We look forward to working closely with Walgreens and the Team to make this a successful product launch and an unforgettable experience for our contest winners."

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market.   HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.  The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission.  All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement.  Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Sunpeaks Ventures, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries
2. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
3. Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington
4. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
5. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
6. Sunpeaks Ventures Announces Clotamin to Be Sold at Winn-Dixie Locations in South Florida
7. Sunpeaks Ventures Announces Clotamin to be Sold at Bravo Supermarkets in South Florida
8. Sunpeaks Ventures to Participate in ECRM Conference and Expo
9. Sunpeaks Ventures Announces Clotamin to be Sold at Navarro Discount Pharmacies
10. Sunpeaks Ventures Announces Clotamin available on Walgreens.com
11. Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 2017 Research and Markets has announced the addition ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:2/17/2017)... Conn. , Feb. 17, 2017 Arvinas ... of drugs based on protein degradation, today announced the ... receptor (AR) PROTAC during a poster session at the ... (ASCO GU) in Orlando, FL. ... to validate our platform and the potential of PROTACs ...
(Date:2/17/2017)... 2017   Risperdal lawsuits involving gynecomastia (male breast ... use of the atypical antipsychotic medication continue to move ... of Common Pleas, where the state,s Risperdal docket has ... a notice posted on the Court,s website , ... March 9, 2017 at 11:00 a.m. (In Re: Risperdal ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is ... in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly ... one roof. Smiles by Seese serves patients of all ages with excellence in general, ...
(Date:2/17/2017)... VA (PRWEB) , ... February ... ... FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 ... What are the critical reimbursement questions manufacturers should be asking before selecting ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program ... , Trinity Health and the U.S. Soccer Foundation announced today that they have ... communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals ...
(Date:2/17/2017)... GA (PRWEB) , ... February 17, 2017 , ... Like ... to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), ... been a key focus area for hospitals across the nation. While many providers are ...
Breaking Medicine News(10 mins):